A Targetable Secreted Neural Protein Drives Pancreatic Cancer Metastatic Colonization and HIF1α Nuclear Retention.

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with most patients receiving palliative chemotherapy.
• Metastasis to the liver is a major cause of mortality in PDAC patients.
• Understanding the molecular mechanisms driving PDAC metastasis is crucial for developing effective therapies.

Purpose of the Study:

• To identify and characterize novel molecular players involved in PDAC metastatic progression.
• To investigate the role of neuronal pentraxin 1 (NPTX1) and its receptor AMIGO2 in PDAC liver metastasis.
• To evaluate the therapeutic potential of targeting the NPTX1-AMIGO2 axis.

Main Methods:

• Molecular, genetic, biochemical, and pharmacologic experiments were employed.
• Overexpression and function of NPTX1 and AMIGO2 in PDAC cells were assessed.
• The effect of NPTX1-AMIGO2 signaling on hypoxic growth and HIF1α was investigated.
• Therapeutic efficacy of an anti-NPTX1 monoclonal antibody was evaluated in preclinical models.

Main Results:

• NPTX1 is overexpressed in PDAC cells during metastatic progression and acts via its receptor AMIGO2.
• NPTX1-AMIGO2 signaling promotes PDAC liver colonization by enhancing hypoxic growth and HIF1α activity.
• NPTX1 is upregulated in human PDAC tumors and liver metastases.
• Therapeutic targeting of NPTX1 with a monoclonal antibody significantly reduced liver metastasis and primary tumor growth.

Conclusions:

• The NPTX1-AMIGO2 axis is a critical upstream regulator of the HIF1α-driven hypoxia response in PDAC.
• This axis promotes PDAC liver metastasis, representing a novel therapeutic target.
• Targeting NPTX1 demonstrated superior efficacy over chemotherapy in preclinical models for inhibiting liver metastasis.